title: High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.
abstract: We have analyzed patients with previously untreated chronic lymphocytic leukemia with del11q fluorescence in situ hybridization (FISH) abnormality (n = 196) in this study. Detection of the 11q22.3 used a multicolor FISH technique. Patients with del11q fell into two major FISH subsets-sole del11q (n = 64) and del11q with del13q (n = 132). FISH subsets were compared using the median del11q FISH% (>58%, high vs. ≤58%, low). Overall survival (OS) and time to first treatment (TTFT) were estimated using Kaplan-Meier plots (log rank). Multivariate analysis was performed to assess the association between FISH% of del11q and outcomes. Patients with sole del11q were similar to del11q with del13q in terms of TTFT and OS. Patients with high FISH% of del11q had significantly shorter OS and TTFT as compared with patients with low FISH%, particularly in sole del11q; this negative impact of high FISH% of del11q on OS and TTFT was diminished with coexistent del13q. In multivariate analysis, high FISH% of del11q was a significant predictor for shorter OS and TTFT. A comparison of these del11q subsets with a separate cohort of (n = 673) previously untreated patients with sole del13q showed that the high FISH% del11q cohort had a significantly shorter TTFT and OS. In addition, bulky disease by physical examination or computed tomography imaging was infrequent at presentation in patients with del11q. High FISH% of del11q can reliably discriminate higher risk patients with chronic lymphocytic leukemia. Presence of coexistent del13q should be accounted for while prognosticating patients with del11q.
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Preetesh
authors: P
authors: Jain
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Michael
authors: M
authors: Keating
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Phillip A
authors: PA
authors: Thompson
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Long
authors: L
authors: Trinh
authors: Department of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Xuemei
authors: X
authors: Wang
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: William
authors: W
authors: Wierda
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Alessandra
authors: A
authors: Ferrajoli
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Jan
authors: J
authors: Burger
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Hagop
authors: H
authors: Kantarjian
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Zeev
authors: Z
authors: Estrov
authors: Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Lynne
authors: L
authors: Abruzzo
authors: Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Susan
authors: S
authors: O'Brien
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002872:Chromosome Deletion; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate